Jefferies on BioAge Labs Inc (BIOA): lower dose data reinforces potential BIC, 'layers of momentum build'

April 21, 2026 2:46 PM

Jefferies analyst Roger Song reiterated a Buy rating and $62.00 price target on BioAge Labs Inc (NASDAQ: BIOA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found